INN – Dornase alfa

Genetically engineered variant of the natural human enzyme that breaks down extracellular DNA.

Indications: symptomatic therapy in combination with standard therapy of cystic fibrosis in patients with the value of Forced Vital Capacity (FVC) at least 40% of the norm to improve lung function.

Dornase alpha is a basic mucolytic drug for the treatment of cystic fibrosis.

  • Rapid and significant reduction of sputum viscosity
  • Significant improvement in respiratory function
  • Reducing the risk of upper respiratory infection

Generium is the first company in the world to develop and produce dornase alpha biosimilar.